Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Tiago Abreu-Mota"'
Autor:
Tiago Abreu-Mota, Katie R. Hagen, Kurt Cooper, Peter B. Jahrling, Gene Tan, Christoph Wirblich, Reed F. Johnson, Matthias J. Schnell
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-16 (2018)
There is currently no approved vaccine for Lassa fever virus (LASV). Here, Abreu-Mota et al. develop an inactivated, adjuvanted vaccine candidate expressing LASV glycoprotein (GPC) in a rabies virus vector, and show that non-neutralizing LASV GPC-spe
Externí odkaz:
https://doaj.org/article/515d6b50b90b48d2976fee557e117292
Autor:
Anna-Friederike Marx, Sandra M. Kallert, Tobias M. Brunner, José A. Villegas, Florian Geier, Jonas Fixemer, Tiago Abreu-Mota, Peter Reuther, Weldy V. Bonilla, Jelizaveta Fadejeva, Mario Kreutzfeldt, Ingrid Wagner, Patricia Aparicio-Domingo, Leo Scarpellino, Mélanie Charmoy, Daniel T. Utzschneider, Claudia Hagedorn, Min Lu, Karen Cornille, Karsten Stauffer, Florian Kreppel, Doron Merkler, Dietmar Zehn, Werner Held, Sanjiv A. Luther, Max Löhning, Daniel D. Pinschewer
Raw data underlying the publication
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0438be1f4fda60bf438a80bbf2ea221
Autor:
Matthias J. Schnell, Gabrielle Scher, Melissa J. Ferguson, Tiago Abreu-Mota, AnnaMarie Testa, Rachael Lambert, Catherine Yankowski, Christoph Wirblich, Leonard P. Ruiz, William Rinaldi, Rohan Keshwara, Drishya Kurup, Christine R. Fisher
Publikováno v:
J Infect Dis
Background The objective of this study is to evaluate the immunogenicity of adjuvanted monovalent rabies virus (RABV)–based vaccine candidates against Ebola virus (FILORAB1), Sudan virus (FILORAB2), Marburg virus (FILORAB3), Lassa virus (LASSARAB1)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d02effb5cdcc0bb8403235af5b81382
https://pubmed.ncbi.nlm.nih.gov/33421072
https://pubmed.ncbi.nlm.nih.gov/33421072
Autor:
Katie R. Hagen, Amy B. Papaneri, Matthias J. Schnell, David R. Liu, Tiago Abreu-Mota, Reed F. Johnson, Rohan Keshwara, Christoph Wirblich
Marburg virus (MARV) is a filovirus related to Ebola virus (EBOV) associated with human hemorrhagic disease. Outbreaks are sporadic and severe, with a reported case mortality rate of upward of 88%. There is currently no antiviral or vaccine available
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::930c643ee751510dbd8ebed00599cda9
https://europepmc.org/articles/PMC6401435/
https://europepmc.org/articles/PMC6401435/
Autor:
Kurt Cooper, Peter B. Jahrling, Matthias J. Schnell, Tiago Abreu-Mota, Reed F. Johnson, Katie R. Hagen, Christoph Wirblich, Gene Tan
Publikováno v:
Nature Communications
Nature Communications, Vol 9, Iss 1, Pp 1-16 (2018)
Repositório Científico de Acesso Aberto de Portugal
Repositório Científico de Acesso Aberto de Portugal (RCAAP)
instacron:RCAAP
Nature Communications, Vol 9, Iss 1, Pp 1-16 (2018)
Repositório Científico de Acesso Aberto de Portugal
Repositório Científico de Acesso Aberto de Portugal (RCAAP)
instacron:RCAAP
Lassa fever (LF), caused by Lassa virus (LASV), is a viral hemorrhagic fever for which no approved vaccine or potent antiviral treatment is available. LF is a WHO priority disease and, together with rabies, a major health burden in West Africa. Here
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f6dd1ee17afbfa4cd404dc8d0bddeb1
https://pubmed.ncbi.nlm.nih.gov/30310067
https://pubmed.ncbi.nlm.nih.gov/30310067